Shares of 4basebio PLC (LON:4BB – Get Free Report) traded down 2% during mid-day trading on Wednesday . The company traded as low as GBX 1,200 ($15.15) and last traded at GBX 1,200 ($15.15). 3,555 shares traded hands during trading, a decline of 19% from the average session volume of 4,376 shares. The stock had previously closed at GBX 1,225 ($15.46).
4basebio Stock Performance
The company has a market capitalization of £153.34 million, a price-to-earnings ratio of -1,534.62 and a beta of 1.09. The firm has a fifty day simple moving average of GBX 1,294.67 and a 200 day simple moving average of GBX 1,408.93. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52.
Insider Activity
In related news, insider Heikki Lanckriet bought 46,500 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was acquired at an average price of GBX 1,325 ($16.72) per share, with a total value of £616,125 ($777,641.05). Insiders own 68.44% of the company’s stock.
About 4basebio
4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines.
Featured Articles
- Five stocks we like better than 4basebio
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Options Trading – Understanding Strike Price
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
